The anti-PD-1 immunotherapy pembrolizumab confers survival benefit over standard chemotherapy in patients with recurrent or metastatic head and neck cancer in the first-line setting, reveals the topline results of the KEYNOTE-048* study presented at ESMO 2018.
Patients with advanced, unresectable melanoma may derive overall survival (OS) and progression-free survival (PFS) benefits when treated with a nivolumab plus ipilimumab combination or nivolumab alone, according to 4-year results of the phase III CheckMate 067* trial presented at ESMO 2018.
The drug combination comprising gemcitabine, cisplatin, and S-1 (GCS) led to significant survival benefits compared with the standard dual chemotherapy regimen of gemcitabine and cisplatin (GC) among patients with advanced biliary tract* cancer (BTC), according to results of the KHB01401–MITSUBA** trial presented at ESMO 2018.
Taking a high daily dose multi-strain probiotic may help reduce incidence of mild-to-moderate chemotherapy-induced diarrhoea (CID), a side effect commonly experienced by cancer patients, suggests a randomized study presented at ESMO 2018.
Combining the anti-PD-L1 avelumab with the VEGFR* blocker axitinib significantly improves progression-free survival (PFS) compared with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC), according to the JAVELIN Renal 101** trial.
Treatment with the PD-L1 inhibitor atezolizumab on top of standard chemotherapy with nab-paclitaxel significantly improves progression-free survival (PFS) in triple-negative breast cancer (TNBC) compared with nab-paclitaxel alone, top-line results from the IMpassion* 130 trial reveal. In particular, median overall survival (OS) was 10 months longer with atezolizumab among PD-L1-positive (PD-L1+) patients in an interim analysis.
Patients with previously treated metastatic gastric adenocarcinoma had improved overall survival (OS) when a trifluridine-tipiracil combination was added to a supportive care regimen compared with best supportive care alone, according to findings of the phase III TAGS* trial.
De-escalating therapy falls short of expectations to reduce toxicity in patients with low-risk human papillomavirus-positive (HPV+) oropharyngeal carcinoma, the De-ESCALaTE HPV trial has shown, supporting the current standard of care which is chemotherapy with cisplatin and radiotherapy.
Adding local radiotherapy (RT) on top of standard of care (SoC) improved overall survival (OS) in men with newly diagnosed oligometastatic (ie, low disease burden [Tany Nany M1]) prostate cancer (PCa), according to the STAMPEDE* trial presented at ESMO 2018.
Drawing from experience as a key investigator in landmark
clinical trials (including PALOMA, MONALEESA and
MONARCH), and his clinical experience with
CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his
insights into the current evidence of using CDK4/6 inhibitors
to treat HR+/HER2- ABC.
Pembrolizumab monotherapy improves overall
survival (OS) and cancer control compared with platinum-based chemotherapy in
patients with untreated locally advanced or metastatic programmed death-ligand
1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11
or KEAP1 mutation status, according to results of the phase III